Zacks Small Cap Research on MSN
CVKD acquires 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT)
By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results